Clinical Trials Browser

Esophageal Neoplasms × camrelizumab × Clear all

NCT07530094 2026-04-15

STELLAR01

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT05176002 2025-11-19

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Phase 1/2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06086457 2024-07-16

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Phase 2 Recruiting

Gastrointestinal

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

NCT05637268 2022-12-05

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT05476380 2022-07-27

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT04390945 2022-02-03

Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT05183958 2022-01-11

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT04286958 2021-12-10

ESCC

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Phase 3 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT04426955 2021-09-16

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Phase 3 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT04654403 2021-08-23

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Phase NA Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04616040 2020-11-04

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Not yet recruiting

Gastrointestinal

Esophageal Neoplasms

NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

NCT04512417 2020-08-13

A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT03222440 2019-12-04

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Phase NA Completed

Gastrointestinal

Esophageal Neoplasms

NCT03671265 2019-01-09

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Phase NA Unknown

Gastrointestinal

Esophageal Neoplasms